Vittoria Biotherapeutics
PrivateLast Round
Private Financing
Extension
Nov 12, 2024
Total Funding Raised
$35M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Vittoria Biotherapeutics operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Private Financing Extension round in November 2024.
Vittoria Biotherapeutics is a biotechnology company developing novel CAR T-cell therapies that transcend the limitations of current cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vittoria Biotherapeutics Comparables
Compare Vittoria Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| March Biosciences | 89% | |
| Wugen | 83% | |
| Mustang Bio Inc | 78% |
For institutional investors. Book with your work email.
Vittoria Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Financing Extension | Nov 12, 2024 | ||||
| Series A | Nov 14, 2023 | ||||
| Seed | Jun 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vittoria Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Private Financing Extension, Seed, Series A |
| University of Pennsylvania Office of Investments | Private Financing Extension, Series A |
| RM Global Partners | Private Financing Extension |
| Tellus BioVentures | Private Financing Extension, Seed, Series A |
| Valley Forge Investment Corporation | Private Financing Extension, Series A |
| The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) | Series A |
| BioAdvance Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 46% MoM.
- Dec 3, 2025
Attended the 10th annual Penn Center for Innovation's Celebration of Innovation.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
Vittoria Biotherapeutics, Inc. is developing LampTAC, a modular, cell-intrinsic protein degradation platform that enables genome-editing-free engineering of next-generation cell therapies.
For institutional investors. Book with your work email.
Vittoria Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vittoria Biotherapeutics's valuation, stock price, and market status.
Is Vittoria Biotherapeutics a public or private company?
Vittoria Biotherapeutics is a private company.
What is the current stock price of Vittoria Biotherapeutics?
Vittoria Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Vittoria Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vittoria Biotherapeutics worth (valuation)?
Valuation information for Vittoria Biotherapeutics is not publicly available.
Can I buy Vittoria Biotherapeutics stock?
Vittoria Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vittoria Biotherapeutics's last funding round?
Vittoria Biotherapeutics's most recent funding round was Private Financing Extension on November 12, 2024.
Who are the main investors in Vittoria Biotherapeutics?
Key investors in Vittoria Biotherapeutics include Valley Forge Investment Corporation.
Will Vittoria Biotherapeutics IPO soon?
No public IPO plans have been announced for Vittoria Biotherapeutics.
How can I track Vittoria Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vittoria Biotherapeutics's shares on secondary markets.